Navigation Links
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
Date:9/24/2007

PITTSBURGH, Sept. 24 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") today announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of amyotrophic lateral sclerosis (ALS).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO )

This randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers is being closely followed by a multiple ascending dose study in healthy subjects. Both studies are designed to evaluate the safety, tolerability and pharmacokinetics of KNS-760704 in human subjects.

"The initiation of Phase 1 represents a significant milestone in Knopp's efforts to develop a safe and effective therapy for a serious unmet medical need," said Michael Bozik, M.D., president and chief executive officer of Knopp. "We look forward to completing these safety studies and moving rapidly to advance the compound into initial clinical trials in ALS patients."

About KNS-760704

KNS-760704 is an orally administered small molecule in clinical development by Knopp for the treatment of amyotrophic lateral sclerosis (ALS). The drug is an optical enantiomer of a selective, high affinity dopamine agonist marketed in other neurological indications. Both KNS-760704 and the marketed agonist demonstrate neuroprotective properties independent of dopamine receptor activity, but KNS-760704 exhibits greatly reduced dopamine receptor affinity. This makes it possible to clinically evaluate the potential neuroprotective activity of KNS-760704 over a broad dose range.

About ALS

Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease, is a rapid, universally fatal neurodegenerative disorder characterized by progressive muscle weakness and wasting. ALS affects adults in the prime of life and creates a substantial burden for caregivers. U.
'/>"/>

SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., Md., Dec. 1 Sleep Solutions®...ider for home testing and evaluation of sleep-diso...hard Hassett, M.D., as its chief executive officer...ealthcare, during its growth from a $250 million h...stry leader in total population health, and its su...
(Date:12/1/2009)..., N.M., Dec. 1 Exagen Diagnostics,...covers, develops and markets proprietary genomic t...nn as chairman of the company,s board of directors...ng Exagen, Glenn was managing partner of Windamere...ssful biomedical companies including Prometheus La...
(Date:12/1/2009)...BEIJING, Dec. 1 /PRNewswire-Asia/ -- Sinovac Biote...harmaceutical products in China, announced today t...its H1N1 vaccine, PANFLU.1(TM),from China,s Minis... national,purchase plan. Under this purchase order... million doses of PANFLU.1 (TM) (15ug/0.5ml) for t...
Breaking Medicine Technology:Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 2Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 1Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 2Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 4Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 5Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3Seguro Acquires Worldwide Rights to Johns Hopkins Abdominal Surgery Device 5560 1
...ively Treats Adult Patients with Moderate to Seve...e, Diagnosis of Psoriatic Arthritis or Recent...s patients,achieve efficacy when they receive cont...red to patients who interrupt their therapy, accor...Dermatology and Venereology,(EADV) Congress in Par...
...Inc.,(Nasdaq: VRUS ) management will present at t...from September 22-25, 2008 at the Grand Hyatt Hote...hief Executive Officer,will provide an overview of... 4:00 PM - 4:30 PM (ET)., To access a live webcas... to the "Events & Presentations" section of the In...
Other Medicine Technology:Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 2Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 3Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 4Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 5Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 6Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 7Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 8Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th 2
(Date:12/1/2009)...es H1N1 vaccination because pandemic,s course rema...ealthDay News) -- A U.S. health official said Tues... the wane nationally, but many experts agreed the ..., The flu is now widespread in 32 states -- down f...en, director of the U.S. Centers for Disease Contr...
(Date:12/1/2009)... , RESEARCH TRIANGLE PARK, N.C., Dec. 1 /PRNe...ated in 2001 and have expanded over the years serv.... The facility which was originally set up in an a...acy services, as part of the suite of services by ...dustry as a valuable offering. ,, The pharmacy ...
(Date:12/1/2009)..., WASHINGTON, Dec. 1 ... for International Development: ,, Chairman Ker...ttee. ,, I am honored to be nominated by Presid...States Agency for International Development, and I...y. ,, Secretary of State Clinton has expressed...
(Date:12/1/2009)...mber 1, 2009) The ADEAGies Foundation will honor ...ent Award at the Gies Awards celebration to be hel...unction with the 2010 ADEA Annual Session & Exhibi...ation, and Achievement recognize contributions to,...nitiatives. For a complete listing of Gies Award w...
(Date:12/1/2009)...r cardiovascular system tied to academic achieveme...thDay News) -- A strong cardiovascular system in y...tter school grades and more overall success later ...st doctors and laypeople know (or should know) the...dies, the authors of a new study, appearing in thi...
Breaking Medicine News(10 mins):Health News:Swine Flu Waning, But Could Return 2Health News:Swine Flu Waning, But Could Return 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 2Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 4Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 5Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 6Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 7Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 8Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 9Health News:The Forsyth Institute receives the William J. Gies Award for outstanding achievement 2Health News:Exercise May Lead to a Smarter, More Successful You 2Health News:Exercise May Lead to a Smarter, More Successful You 3
...one policeman and affected at least 20 deployed to...trict, a policeman said Saturday. The state gov...ssa State Armed Police // in three villages of Sam...en getting clean water," said Raju Barali, who is ...
... feel that there is a requirement for having a sta...review article published in the July/August 2005 J...stablished treatment guidelines // to support doc...cy (PI) disorders, who do not produce adequate lev...
...ws that our attitude towards food has cost us a fo.... Deep in Arizona, one lone, but dedicated univers...ng his students to count food // in, count food ou... Studies have show that in agriculture, where fie...
...ects the body from tissue damage has also been fou...helps the body's healthy cells survive the effects...ein was also found to encourage the growth of tumo...enetically dissimilar with respect to the Bcl gene...
...West are turning to yoga now to keep themselves fi...ides a good feeling and enormous satisfaction," Ku.... "If you practise yoga regularly you become...een a real yoga boom with prominent stars like Mad...
...ular and Molecular Biology (CCMB), Hyderabad has u... the way for detecting the mechanisms that prevent...ika Pal Bhadra and Utpal Bhadra have been instrume...nes (heterochromatin), which are responsible for r...
Other Medicine News:Health News:Researchers Feel The Need For Standards Of Practice In Immunoglobulin Therapy 2
STAAR ELASTIC LENS
...ers at Pfizer used wavefront sensing to invent the...ative TECNIS features a patented modified prolate ...aberration, which compensates for the positive sph...IS is the first and only IOL with a clinically dem...
SoFlex Multipiece Foldable IOL
...ariflex® Intraocular Lens is indicated for the...lder in whom a cataract lens has been removed. Thi...roprietary silicone material. The exclusive OptiEd... and to facilitate capsular contact. It is easily ...
Medicine Products: